RecruitingNCT06890078
Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients
Optimisation du Diagnostic de Pneumocystose Chez Les Patients Immunodéprimés
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
240 participants
Start Date
Jul 8, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- adult patients with suspected pneumocystis
- with an indication for bronchial fibroscopy for BAL or induced sputum
- no opposition to the research from the adult patient or his or her next of kin research for patients unable to express their non-opposition
Exclusion Criteria3
- Pneumocystis treated for more than 72 hours
- pregnancy/breast-feeding
- adult patients deprived of liberty, protected
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERBiological sampling
Mouthwash, nasopharyngeal swab, blood sampling
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06890078
Related Trials
Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients
NCT073218081 location
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
NCT048510151 location
Personalized Immunological Score for the Prediction of Severe Infectious Events in Immunocompromised Patients and Tailored Management (PERISCOPE)
NCT073795541 location
Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised and Healthy Cohorts
NCT072955351 location